BridgeBio poised to challenge Pfizer after Attruby approval

BridgeBio grabs FDA approval for its ATTR cardiomyopathy drug Attruby, setting up a challenge to market leader Pfizer

Vyndaqel romps away in US, spurring earnings hike from Pfize...

Pfizer claims FDA okay for rare heart disease drug tafamidis

The FDA has given a green light to two formulations of Pfizer’s tafamidis that have become the first drugs to be approved in the US for cardiomyopathy associated with rare disease transthyr

Pfizer set for July FDA verdict on rare heart disease drug

Pfizer is finally closing on approval of its rare disease therapy tafamidis in the US, several years after it first reached the market in Europe.

Pfizer drug reduces mortality in patients with fatal heart d...

Pfizer’s heart disease drug, tafamidis, reduces mortality rates in patients, according to the top-line results of a phase 3 trial.